Cockroach Immunotherapy in Children and Adolescents

Persistent Asthma Clinical Trial

— CRITICAL  

Official title:

Cockroach Immunotherapy in Children and Adolescents

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03541187
• Other study ID #: DAIT ICAC-28
• Secondary ID: UM1AI114271NIAID
• Status: Completed
• Phase: Phase 2
• Start date: July 16, 2018
• Est. completion date: June 3, 2022

Study information

• Verified date: May 2023
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Scientific evidence has shown that, over the past two decades, the combination of cockroach allergy and cockroach exposure is one of the most important factors contributing to the dramatic increase in asthma morbidity seen in inner city children with asthma. Therefore, a major goal of the Inner City Asthma Consortium (ICAC) is to evaluate the efficacy of cockroach immunotherapy in inner city asthma.

The primary objective of the study is to determine if the response to nasal allergen challenge (NAC) will be changed with treatment with cockroach subcutaneous immunotherapy (SCIT) treatment.

Description:

This is a 1:1 randomized, double-masked (blind), placebo-controlled, multicenter trial with 2 treatment arms:

• German Cockroach Subcutaneous Immunotherapy (SCIT) + guideline-based standard asthma care, OR

• Placebo (for German Cockroach Subcutaneous Immunotherapy [SCIT]) + guideline-based standard asthma care

Eighty participants 8 to 17 years of age who are sensitized to cockroach, have asthma, and a positive cockroach Nasal Allergen Challenge (NAC) before treatment randomization will be enrolled.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 82
• Est. completion date: June 3, 2022
• Est. primary completion date: June 2, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 8 Years to 17 Years

Eligibility

Inclusion Criteria:Subject(s)

• And/or parent guardian must be able to understand and provide informed consent;

• Age at date of recruitment (e.g., screening): 8 to 17 years of age

• Have a primary place of residence in one of the pre-selected recruitment census tracts (Reference: Inner-City Asthma Consortium):

--Note: Subjects who do not live in the pre-selected census tracts but live within the Office of Management and Budget (OMB) defined Metropolitan Statistical Area and have publicly-funded health insurance will qualify for inclusion.

• Have a history of persistent asthma, for a minimum of 1 year before study entry:

• A diagnosis of asthma will be defined as a report by the caretaker that the subject had a clinical diagnosis of asthma made by a clinician =1 year ago, resulting in a prescription of preventative asthma medication, and

• Must have persistent asthma as defined by the current need for at least 88 mcg fluticasone (or the equivalent of another inhaled corticosteroid) to control asthma at the time of screening.

• At the time of randomization, the subject's asthma must be well controlled as defined by:

• A Forced Expiratory Volume in 1 second (FEV1) =80% predicted, and

• An Asthma Control Test (ACT) or Childhood Asthma Control Test (CACT) score =20.

• Is sensitive to German cockroach as documented by:

• a positive (=3 mm greater than negative control) skin prick test result, and

• detectable German cockroach specific Immunoglobulin E (IgE) (= 0.35 kUA/L).

• Have no known contraindications to therapy with glycerinated German cockroach allergenic extract or placebo;

• Have a positive cockroach nasal challenge, as defined by reaching a Total Nasal Symptom Score (TNSS) of =6 or a sneezing score of 3 at dose 2 or above during the challenge before randomization; and

• Have documentation of current medical insurance with prescription coverage at randomization.

Exclusion Criteria:Subject(s)

• Unable or unwilling to give written informed consent or comply with the study protocol;

• That is pregnant or lactating;

• That are post-menarcheal females must be abstinent or use a medically acceptable birth control method throughout their participation in the study (e.g. oral, subcutaneous, mechanical, or surgical contraception);

• That cannot perform spirometry and peak flow at treatment randomization;

• That have an asthma severity classification at the time of treatment randomization of severe persistent, using the The National Asthma Education and Prevention Program (NAEPP) classification, as evidenced by at least one of the following:

• Requires a dose >500 mcg of fluticasone per day or the equivalent of another inhaled corticosteroid,

• Has received more than 2 courses of oral or parenteral corticosteroids in the last 12 months or one course within the last 3 months prior to study entry,

• Has been treated with depot steroids within the 3 months prior to study entry,

• Has been hospitalized for asthma within the 6 months prior to study entry, or

• Has had a life-threatening asthma exacerbation that required intubation, mechanical ventilation, or that resulted in a hypoxic seizure within 2 years prior to study entry.

• Does not have access to a phone (needed for scheduling appointments);

• Has received allergen immunotherapy (Sublingual Immunotherapy [SLIT] or Subcutaneous Immunotherapy [SCIT]) in the last 12 months or, who plan to initiate or resume allergen immunotherapy during the study;

• Has received biologic therapy (e.g., anti-Immunoglobulin E [IgE], anti-IL-4, anti-IL-5) within 6 months of study entry;

• Has received an investigational drug in the 30 days prior to recruitment or who plan to use an investigational drug during the study;

• Has past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may:

• pose additional risks from participation in the study,

• may interfere with the subject's ability to comply with study requirements, or

• that may impact the quality or interpretation of the data obtained from the study.

• Who have nasal polyps or other major structural abnormalities in their nasal cavities as assessed by anterior rhinoscopy,

• Who meet any of the following criteria are not eligible for enrollment and may not be reassessed:

• That plan to move from the area during the study period,

• Have a history of anaphylaxis grade 3 or higher as defined by World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System,

• Have unstable angina, significant arrhythmia, uncontrolled hypertension, history of autoimmune disease, or other chronic or immunological diseases that, in the opinion of the investigator, might interfere with the evaluation of the investigational product or pose additional risk to the subject,

• Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator,

• may pose additional risks from participation in the study,

• may interfere with the subject's ability to comply with study requirements,

• or that may impact the quality or interpretation of the data obtained from the study.

• Are using tricyclic antidepressants or beta-adrenergic blocker drugs (both oral and topical).

Related Conditions & MeSH terms

• Asthma
• Persistent Asthma

Intervention

Biological:
• German cockroach allergenic extract
Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467).
• Placebo for German cockroach allergenic extract
Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%).

Locations

Country	Name	City	State
United States	Children's Hospital Colorado	Aurora	Colorado
United States	Johns Hopkins University	Baltimore	Maryland
United States	Boston Medical Center	Boston	Massachusetts
United States	Ann and Robert Lurie Children's Hospital of Chicago	Chicago	Illinois
United States	Cincinnati Children's Hospital	Cincinnati	Ohio
United States	University of Texas Southwestern Medical School	Dallas	Texas
United States	Henry Ford Health System: Division of Allergy and Immunology	Detroit	Michigan
United States	Columbia University Medical Center	New York	New York
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	St. Louis Children's Hospital: Allergy, Immunology and Pulmonary Medicine Program	Saint Louis	Missouri
United States	Children's National Medical Center - IMPACT DC	Washington	District of Columbia

Sponsors (3)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	Inner-City Asthma Consortium, Rho Federal Systems Division, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	EXPLORATORY: Composite Asthma Severity Score (CASI)-by Treatment Group	The Composite Asthma Severity Index (CASI) is a comprehensive severity scale combining multiple facets of asthma severity: impairment, risk, and treatment. The CASI score ranges from 0 to 20 points, with higher scores indicating higher levels of severity, and includes 5 domains: day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations.	Month 10, Month 12
Other	EXPLORATORY: Number of Days With Asthma Symptoms-by Treatment Group	Defined by the presence of wheezing or tightness in the chest, or cough.	Baseline (Pre-treatment) through Study Completion, an Average of 1 Year
Other	EXPLORATORY: Number of Nights With Asthma Symptoms-by Treatment Group	Defined by participant waking up during the night due to the presence of wheezing or tightness in the chest, or cough.	Baseline (Pre-treatment) through Study Completion, an Average of 1 Year
Other	EXPLORATORY: Number of Days With Albuterol Use-by Treatment Group	Albuterol is a bronchodilator used for asthma control.	Baseline (Pre-treatment) through Study Completion, an Average of 1 Year
Other	EXPLORATORY: Number of Nights With Albuterol use-by Treatment Group	Albuterol is a bronchodilator used for asthma control.	Baseline (Pre-treatment) through Study Completion, an Average of 1 Year
Other	EXPLORATORY: Asthma Treatment step-by Treatment Group	Defined by medication requirements for asthma control.	Baseline (Pre-treatment) through Study Completion, an Average of 1 Year
Other	EXPLORATORY: Number of Asthma exacerbations-by Treatment Group	Asthma exacerbation defined as a prescribed course of systemic steroids by a clinician or initiation of a course of systemic steroids by a participant or a hospitalization during the study.	Baseline (Pre-treatment) through Study Completion, an Average of 1 Year
Other	EXPLORATORY: Spirometry Measurement: Forced Expiratory Volume in 1 Second (FEV1)-by Treatment Group	FEV1 is air volume exhaled in 1 second during spirometry and is a measure of asthma severity.	Baseline (Pre-treatment) through Study Completion, an Average of 1 Year
Other	EXPLORATORY: Comparison of Rhinitis Symptom severity-by Treatment Group	Measured using the Modified Rhinitis Symptom Utility Index.	Baseline (Pre-treatment) through Study Completion, an Average of 1 Year
Other	EXPLORATORY: Comparison of Rhinitis Treatment step-by Treatment Group	Defined by medication requirements for rhinitis control.	Baseline (Pre-treatment) through Study Completion, an Average of 1 Year
Other	EXPLORATORY: Change in German Cockroach-Specific Serum IgG Over Time-by Treatment Group	Outcome is the ratio of geometric means for baseline German cockroach-specific serum Immunoglobulin G (IgG) vs. post-baseline German cockroach-specific serum IgG. Numerator is geometric mean post-baseline IgG; denominator is baseline IgG.This result is an indicator of immune modulation over time, however its clinical significance is unclear.	Baseline (Pre-treatment) through Study Completion, an Average of 1 Year
Other	EXPLORATORY: Change in German Cockroach-Specific Component Allergens Over time-by Treatment Group	Including but not limited to the following component allergens: Bla g 1, Bla g 2, Bla g 4, Bla g 5 and Per a 7.	Baseline (Pre-treatment) through Study Completion, an Average of 1 Year
Other	EXPLORATORY: Change in Cockroach Skin Test Reactivity Over Time-by Treatment Group	As a measure of response to cockroach immunotherapy.	Baseline (Pre-treatment) through Study Completion, an Average of 1 Year
Other	EXPLORATORY: Change in Cockroach-Specific Blocking Antibodies Over Time-by Treatment Group	To explore serum measurement(s) of in-vitro cockroach antigen binding to B-cells.	Baseline (Pre-treatment) through Study Completion, an Average of 1 Year
Other	EXPLORATORY: Change in Cockroach-Specific T Cell Response-by Treatment Group	Limited to Part A only: Peripheral blood mononuclear cells (PBMCs) will be evaluated for the magnitude and phenotype of the Cockroach (CR)-specific T cell response to CR immunotherapy.	Baseline (Pre-treatment) through Study Completion, an Average of 1 Year
Other	EXPLORATORY: Change in Peripheral Blood Mononuclear Cells (PBMCs) Gene Expression Response to Cockroach (CR) Stimulation Over Time-by Treatment Group	To identify the changes in PBMC gene expression response to cockroach stimulation over time and compare those changes between the treated (German cockroach allergenic extract ) and untreated (placebo) group.	Baseline (Pre-treatment) through Study Completion, an Average of 1 Year
Other	EXPLORATORY: Change in Nasal Lavage Gene Expression Over Time-by Treatment Group	To identify the changes in nasal lavage gene expression response to cockroach stimulation over time and compare those changes between the treated (German cockroach allergenic extract ) and untreated (placebo) group.	Baseline (Pre-treatment) through Study Completion, an Average of 1 Year
Primary	Change in Mean Total Nasal Symptom Score (TNSS) From Baseline to 12 Months Between Cockroach SCIT and Placebo	The study's primary endpoint is the mean TNSS change from baseline to 12 months, calculated as the difference between baseline and 12-month mean TNSS up to baseline responsive dose. TNSS (0-12) is the sum of three participant-assessed scores for rhinorrhea, congestion, itching, and staff-monitored sneezing, rated 0=None, 1=Mild, 2=Moderate, 3=Severe. Analysis uses ANCOVA modeling mean TNSS difference with factors for treatment arm, site, and baseline mean TNSS. Least square means (LSmeans), SEs, difference in LSmeans between treatment and placebo groups, 95% CI, and p-value are reported. A greater change in the LSmeans indicates a better outcome.	After 12 months
Secondary	Number of Immunotherapy Related Adverse Events and Number of Immunotherapy Related Serious Adverse Events in the Course of Treatment.	Summary tables will present the total number of Immunotherapy related adverse event within the course of treatment.	After 12 months
Secondary	Change in Area Under the Curve (AUC) Total Nasal Symptom Score (TNSS) From Baseline to 12 Months Between Cockroach SCIT and Placebo	The Total Nasal Symptom Score (TNSS) Area under the curve (AUC) will be calculated separately at baseline and 12 months for each subject using the trapezoidal rule and divided by their baseline reactive dose. TNSS (0-12) is the sum of three participant-assessed scores for rhinorrhea, congestion, itching, and staff-monitored sneezing, rated 0=None, 1=Mild, 2=Moderate, 3=Severe. Analysis uses ANCOVA modeling AUC TNSS with factors for treatment arm, site, and baseline TNSS AUC. Least square means (LSmeans), SEs, difference in LSmeans between treatment and placebo groups, 95% CI, and p-value are reported. A greater change in the LSmeans indicates a better outcome.	After 12 months
Secondary	Change in 12-month Responsive Dose Between Cockroach SCIT and Placebo	The 12-month responsive dose is being calculated as the first dose that triggers a reaction of TNSS (Total Nasal Symptom Score) greater than or equal to 6 or a sneeze score of 3, whichever occurs first, in a sequence of up to 9 doses. To estimate the hazard ratio and 95% confidence interval, we are conducting an analysis using Cox regression with censoring, while controlling for the baseline responsive dose and site. Participants who do not experience a reaction before reaching the last dose will be considered right-censored.	After 12 months
Secondary	Change in Log-transformed German Cockroach-specific IgE From Baseline to 12 Months Between Cockroach SCIT and Placebo	The difference in log-transformed German Cockroach-specific IgE between baseline and 12 months is being modeled using ANCOVA with factors for treatment arm, site, and the respective log-transformed IgE baseline as covariates. For each treatment group, we present least square means (LSmeans) and their associated standard errors (SEs). We report the difference in LSmeans between the treatment and placebo groups, along with the associated 95% confidence interval (CI) and p-value.	After 12 months
Secondary	Change in Log-transformed German Cockroach-specific IgG4 From Baseline to 12 Months Between Cockroach SCIT and Placebo	The difference in log-transformed German Cockroach-specific IgG4 between baseline and 12 months is being modeled using ANCOVA with factors for treatment arm, site, and the respective log-transformed IgG4 baseline as covariates. For each treatment group, we present least square means (LSmeans) and their associated standard errors (SEs). We report the difference in LSmeans between the treatment and placebo groups, along with the associated 95% confidence interval (CI) and p-value.	After 12 months

External Links

•   Division of Allergy, Immunology, and Transplantation (DAIT)
•   Inner-City Asthma Consortium
•   National Institute of Allergy and Infectious Diseases (NIAID)